Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$13.45 ▲ +0.25
(+1.89%)
MKT CAP: $53.3M • VOL: 14.0K
52W L $8 52W H $23
ROARABLE / RQD
D- • 42/100
PIOTROSKI
1 / 9
ELOX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $6.4M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.4M | -$2.5M | -$17.3M |
| Operating Margin % | — | -38.8% | — |
| Net Income (GAAP) | -$6.0M | -$3.1M | -$17.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.3M | -$4.7M | -$14.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$6.3M | -$4.7M | -$14.3M |
| FCF Margin % | — | -74.1% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.8M | $111.0K | — |
| Total Debt (Short + Long Term) | $0 | $0 | — |
| Total Stockholders' Equity | -$11.9M | -$24.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELOX.